The Definitive
Retatrutide Resource
Comprehensive, peer-reviewed knowledge base covering mechanism of action, clinical trials, safety data, and the latest research on the first triple GIP/GLP-1/glucagon receptor agonist.
New to Retatrutide?
What Is Retatrutide?
Understand the basics of this investigational triple-agonist peptide and why it matters.
Read article 02Mechanism of Action
Learn how retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously.
Read article 03Safety Overview
Review the safety profile, common side effects, and tolerability data from clinical trials.
Read articleFeatured Knowledge
Safety Profile of Retatrutide: Comprehensive Overview from Clinical Data
A thorough review of retatrutide's safety profile based on Phase 1 and Phase 2 clinical trial data, covering gastrointestinal adverse events, laboratory findings, cardiovascular signals, hepatic effects, and outstanding safety questions.
What Is Retatrutide? A Comprehensive Overview of LY3437943
An in-depth introduction to retatrutide (LY3437943), the first-in-class triple GIP/GLP-1/glucagon receptor agonist in development by Eli Lilly for obesity and type 2 diabetes.
Mechanism of Action: How Retatrutide's Triple Receptor Agonism Works
A deep dive into retatrutide's triple GIP/GLP-1/glucagon receptor agonism, explaining how each receptor pathway contributes to the molecule's metabolic effects and why synergistic triple agonism exceeds single- or dual-target approaches.
Explore Topics
Knowledge Base
In-depth articles on pharmacology, mechanism of action, safety, and outcomes.
Clinical Trials
Phase 2 and Phase 3 trial data, enrollment status, and key results.
Comparisons
Side-by-side analysis with semaglutide, tirzepatide, and other GLP-1 agonists.
Blog
Analysis, commentary, and updates on retatrutide research and development.
FAQ
Answers to the most common questions about retatrutide.
Glossary
Definitions of medical and scientific terms used across the knowledge base.
Trial Developments
TRIUMPH-4
TRIUMPH-4: Obesity with Knee Osteoarthritis (First Phase 3 Readout)
The first Phase 3 trial of retatrutide to report results, evaluating weight loss and knee osteoarthritis pain reduction in adults with obesity and knee OA. Demonstrated 28.7% weight loss and 75% pain reduction at 12 mg/68 weeks.
Phase 1 Japan Study
Phase 1 Study in Japanese Subjects (NCT06003465)
A Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of retatrutide in Japanese adults with overweight or obesity, supporting global regulatory submissions including Japan (PMDA).
Phase 2 Body Composition Substudy
Phase 2 Body Composition Substudy
A substudy of the Phase 2 obesity trial evaluating the effects of retatrutide on body composition using dual-energy X-ray absorptiometry (DXA), assessing changes in fat mass, lean mass, and visceral adipose tissue.
Latest from the Blog
The Future of Obesity Pharmacotherapy: From Single Agonists to Combination Approaches
Where obesity treatment is headed — the evolution from GLP-1 monotherapy to multi-receptor agonists and combination strategies, and where retatrutide fits in the expanding pipeline.
Retatrutide Dose Escalation Explained: Why Starting Low Matters
Understanding dose escalation in retatrutide and other GLP-1 class drugs — how gradual titration improves tolerability, what the Phase 2 trial revealed, and implications for clinical practice.
Liver Fat Reduction With Retatrutide: Why the Phase 2 Data Are Significant
An in-depth analysis of retatrutide's approximately 82% liver fat reduction in Phase 2 — what it means for MASLD treatment, why glucagon receptor agonism drives the effect, and how it compares to other therapeutic approaches.